Woodcock Open To Endpoint Flexibility For Rare Diseases

 
• By Sarah Karlin-Smith
  
zebra
Combinations of multiple endpoints may be possible for rare-disease trials, Woodcock says.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Rare Diseases

More from Pink Sheet